Recon: CDC panel recommends infant RSV therapy; RFK says US will stop funding Gavi

• RFK Jr. says U.S. will stop funding global vaccine alliance Gavi (The Washington Post)
• RFK Jr. Is Doing What Vaccine Experts Feared (Bloomberg)
• CDC to hire former head of anti-vaccine group founded by RFK Jr. (CBS)
• CDC vaccine advisers recommend Merck’s RSV therapy for babies (STAT)
• Conducting Remote Regulatory Assessments Questions and Answers (FDA)
• NIH halts grant terminations ‘effective immediately,’ email says (STAT)
• Eric Green was the first institute director forced out of NIH. He still hasn’t been told why (STAT)
• PhRMA CEO: ‘Most-favored nation’ policy isn’t the way to lower drug prices (STAT)
• Walgreens tops quarterly profit estimates as Sycamore deal nears completion (Reuters)
• New Report on Patent Litigation Settlements Says that they are Critically Necessary to Ensure Prompt Generic and Biosimilar Market Entry (FDA Law Blog)

• New EU Rules Limit Chinese Participation In Medtech Procurement (MedTech Insight)
• Weight loss jabs study begins after reports of pancreas issues (BBC)
• UK Trails NHS 10-Year Plan With Launch Imminent (MedTech Insight)
• Fallouh Healthcare Receives Grant Funding From Innovate UK (MedTech Insight)
• Canada Unveils Draft List of Essential Drugs For Universal Pharmacare (Pink Sheet)

• Generic cancer drugs used around the world fail quality tests, investigation shows (STAT)
• After Best Buy sale, what’s next for Current Health (STAT)
• Here’s how Insmed grows to be the next $100 billion biotech (STAT)
• ADHD medication linked to less impulsive behavior, crashes, and crime (STAT)
• Novo Nordisk, seen as lagging in obesity drug race, says it’s playing the long game (STAT)
• Vor Bio bounces back with autoimmune drug pact, $175M private placement (Endpoints)
• Novartis strikes cardiovascular discovery deal with Flagship’s ProFound (Endpoints)
• Opus, Viatris say presbyopia drug succeeds in Phase 3 (Endpoints)
• Altimmune shares slump as weight-loss drug's fatty liver trial data disappoints (Reuters)

• Tandem’s Elizabeth Gasser on patch pump plans, Abbott partnership (MedTech Dive)
• J&J teams with Nvidia, Amazon on fund for AI surgery solutions (MedTech Dive)
• Medtronic recall of capsule delivery devices tied to 33 serious injuries (MedTech Dive)
• Newborn Screening Tests Among FDA Classifications (MedTech Insight)

• Mars’ $36B takeover of Kellanova delayed amid EU investigation (Food Dive)
• Conagra to remove artificial colors in frozen foods by the end of this year (Food Dive)

• Private sector, philanthropy can’t replace Trump administration science cuts (STAT)
• States anxiously wait to find out if cancer tracking and prevention funding from CDC will be renewed (STAT)
• Change in Federal Payment and Collection Options (Federal Register)
• As Trump’s deadline nears, Republicans face substantial disagreement on Medicaid cuts (STAT)
• To tackle race in clinical guidelines, researchers seek alternatives to federal dollars (STAT)
• Trump’s pick to run the CDC walks a fine line on RFK Jr. at Senate hearing (STAT)